Interference of bone marrow CD56+ mesenchymal stromal cells in minimal residual disease investigation of neuroblastoma and other CD45- /CD56+ pediatric malignancies using flow cytometry
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
31066205
DOI
10.1002/pbc.27799
Knihovny.cz E-resources
- Keywords
- flow cytometry, hematology/oncology, mesenchymal stromal cells, minimal residual disease, neuroblastoma,
- MeSH
- CD56 Antigen metabolism MeSH
- Leukocyte Common Antigens metabolism MeSH
- Immunophenotyping MeSH
- Bone Marrow metabolism pathology MeSH
- Humans MeSH
- Mesenchymal Stem Cells metabolism pathology MeSH
- Follow-Up Studies MeSH
- Neuroblastoma diagnosis etiology metabolism MeSH
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma complications metabolism MeSH
- Child, Preschool MeSH
- Prognosis MeSH
- Prospective Studies MeSH
- Flow Cytometry MeSH
- Neoplasm, Residual etiology metabolism pathology MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Child, Preschool MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- CD56 Antigen MeSH
- Leukocyte Common Antigens MeSH
- NCAM1 protein, human MeSH Browser
- PTPRC protein, human MeSH Browser
BACKGROUND: Bone marrow (BM) samples obtained from minimal residual disease (MRD)-negative children with B-cell acute lymphoblastic leukemia (B-ALL) were used in our laboratory as negative biological controls for the development of a neuroblastoma (NBL) flow-cytometric (FC) protocol. The accidental, but systematic, identification of rare cell populations (RCP) mimicking NBL cells (CD45- /CD56+ ) in these samples indicated the need for their thorough immunophenotypic identification, in order to elucidate their possible interference in NBL-MRD assessment. PROCEDURE: RCP observed in BM samples from 14 children recovering from BM aplasia due to intensive chemotherapy for B-ALL were investigated with the following markers: CD81, CD200, CD24, GD2, CD73, CD13, CD90, CD146, CD9, CD117, CD10, CD99, and NG2. BM samples from six newly diagnosed patients with NBL and an NBL cell line were simultaneously investigated as positive controls. RESULTS: The frequency of RCP in B-ALL BM samples was < 1/1 × 104 cells (bulky lysis), and their immunophenotypic profile was indicative of CD56+ mesenchymal stromal cells (MSCs) (CD45- , CD90+ , CD146+ , CD73+ ). Also, RCP expressed CD81 and CD200, simulating NBL cells. The most useful discriminative markers for CD56+ MSCs were CD13 and CD73. An appropriate protocol consisting of two tubes with seven color combinations was further proposed: SYTO-16, GD2 (first tube) or CD73 (second tube)-PE, CD24-ECD, CD13-PC5.5, CD45-PC7, CD81-APC, and CD56-APC700. CONCLUSIONS: RCP that were immunophenotypically similar to NBL were identified as CD56+ MSCs. As these cells might pose an obstacle to accurate NBL disease assessment by FC, especially MRD, an enhanced NBL-FC protocol is proposed for prospective evaluation.
References provided by Crossref.org
